Please assess the completion status of the following clinical trial:

Trial Title: Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed solid tumor~* Has ≥ 2 brain metastases as demonstrated by baseline MRI~  * Patients with only 1 metastasis are eligible provided the metastasis is too large for radiosurgery and not amenable to surgical resection~* Not being considered for surgical resection~* Eligible to undergo whole-brain radiotherapy (WBRT)~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* ANC ≥ 1,000/μL~* Platelet count ≥ 50,000/μL~* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST/ALT ≤ 1.5 times ULN~* INR ≤ 1.5 times ULN~* Sodium normal~* Thyroid-stimulating hormone normal~* Negative pregnancy test~* Fertile patients must use effective contraception before, during, and for ≥ 6 months after completion of study treatment~* No headaches, disequilibrium, vertigo, or dizziness~* No known history of hepatitis B or C~* No concurrent serious systemic disorder (including active infection) that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator~* No history of allergic reactions attributed to riluzole~PRIOR CONCURRENT THERAPY:~* No prior WBRT~* At least 2 weeks since prior systemic chemotherapy~* No systemic chemotherapy during and for ≥ 3 weeks after completion of WBRT~* Radiosurgical boosts to ≤ 3 metastases allowed, based on the discretion of the treating radiation oncologist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Riluzole; Radiation Therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).